Patents by Inventor Haojing Rong

Haojing Rong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRAK4 DEGRADERS AND USES THEREOF
    Publication number: 20230405012
    Abstract: The present invention relates to a method of treating autoimmune/autoinflammatory diseases and hematological malignancies in a subject.
    Type: Application
    Filed: September 1, 2023
    Publication date: December 21, 2023
    Inventors: Haojing RONG, Bradley ENERSON
  • IRAK4 degraders and uses thereof
    Patent number: 11773103
    Abstract: The present invention relates to a method of treating autoimmune/autoinflammatory diseases and hematological malignancies in a subject.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: October 3, 2023
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Haojing Rong, Brad Enerson
  • IRAK4 DEGRADERS AND USES THEREOF
    Publication number: 20230277519
    Abstract: The present invention relates to IRAKIMiD degraders, their liquid formulations, and methods of use thereof for treating cancer.
    Type: Application
    Filed: January 13, 2023
    Publication date: September 7, 2023
    Inventors: Jared Gollob, Jeffrey Davis, Ashwin Gollerkeri, Reginald EWESUEDO, Alice McDonald, Vashali Dixit, Shu-Pei Wu, Michele Mayo, Haojing Rong, Sagar Agarwal, Bradley Enerson, Patrick Henrick, Rachelle Perea, Christopher Ho, William Leong, Duncan Walker
  • METHODS OF TREATING CANCER
    Publication number: 20230233546
    Abstract: The present invention relates to methods of treating solid cancers and hematological malignances using MDM2 degraders.
    Type: Application
    Filed: December 15, 2022
    Publication date: July 27, 2023
    Inventors: Stefanie SCHALM, Dapeng Chen, William Proctor, Joseph Growney, Juliet Williams, Brad Enerson, Yogesh Chutake, Michele Mayo, Jianfeng Qi, Chris Ho, Matthew M. Weiss, Haojing Rong
  • IRAK4 DEGRADERS AND USES THEREOF
    Publication number: 20220274993
    Abstract: The present invention relates to a method of treating autoimmune/autoinflammatory diseases and hematological malignancies in a subject.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 1, 2022
    Inventors: Haojing RONG, Brad ENERSON
  • IRAK4 DEGRADERS AND USES THEREOF
    Publication number: 20220273668
    Abstract: The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 1, 2022
    Inventors: Jared GOLLOB, Jeffrey DAVIS, Alice MCDONALD, Haojing RONG
  • Recombinant Follistatin-FC Fusion Proteins and Use in Treating Duchenne Muscular Dystrophy
    Publication number: 20180362604
    Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin fusion protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.
    Type: Application
    Filed: May 11, 2018
    Publication date: December 20, 2018
    Inventors: Haojing Rong, Andrea Iskenderian, Angela W. Norton, Chuan Shen, Clark Pan